Neuroblastoma Stem Cell Therapy Development

A form of cancer known as neuroblastoma arises from immature nerve cells that can be found in various body regions. The adrenal glands, which share a common ancestor with nerve cells, are the sites where neuroblastoma most frequently develops. Patient survival rates have increased when high-dose chemotherapy is combined with stem cell therapy. Therefore, CD BioSciences has launched neuroblastoma stem cell therapy development services.

Overview of Neuroblastoma

According to histopathology, neuroblastoma is a type of childhood cancer known as a "small blue round cell" neoplasm, which is primarily made up of undifferentiated pediatric malignancies. The neural crest progenitor cells of the sympathoadrenal lineage, known as sympathogonia, are the source of neuroblastoma tumors. The neural crest is a temporary structure made up of multipotent progenitor cells that are present during embryogenesis and emerge from the dorsal portion of the neural tube before migrating throughout the body during mid-gestation. The interaction of various signaling pathways helps to tightly regulate the progenitor cells' high rate of proliferation.

ALK is an Ideal Therapeutic Target in Neuroblastoma

Gain-of-function point mutations in ALK, which codes for the anaplastic lymphoma kinase receptor, alter it in some high-risk NBs, and since it expresses little to no protein in healthy tissue after birth, it makes an excellent therapeutic target.

• ALK Common Mutation Sites
  The majority of ALK mutations found in neuroblastoma are point mutations in the kinase domain, which frequently cause the ALK protein to be constitutively activated. There are three hotspots for ALK point mutations: F1174, F1248, and R1275 in the kinase domain.
• ALK Mutation Induced Neuroblastoma
  While targeted expression of mutated ALK to the developing neural crest induced neuroblastoma in both zebrafish and mice, overexpression of mutated ALK transformed both NIHT3T cells and murine neural crest cells. In preclinical models, activated ALK and MYCN work together to promote the initiation and development of neuroblastoma.
• Research Progress of ALK Inhibitors
  The most common druggable mutations found in neuroblastoma to date are activating mutations of ALK, and strong preclinical evidence has been presented to support activation of ALK as an oncogenic driver in neuroblastoma. Treatment with ALK inhibitors resulted in complete tumor regression in transgenic mice carrying established ALK-driven neuroblastoma, and significant tumor growth inhibition was seen in immunodeficient mice carrying human neuroblastoma xenografts harboring activating ALK mutations.

Our Services

CD BioSciences offers neuroblastoma stem cell therapy development services. The treatment of neuroblastoma has gradually developed into comprehensive treatment methods such as intensive chemotherapy, radiotherapy combined with autologous hematopoietic stem cell transplantation, and the survival rate of high-risk children has been significantly improved. However, there are many challenges in bringing stem cell therapy to full clinical use. Based on our professional laboratory team, we can contribute to the development of stem cell therapy for neuroblastoma.

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

1. Johnsen, John. et al. (2018). Molecular mechanisms and therapeutic targets in neuroblastoma. Pharmacological Research.